Inhibitor Formation in the Era of Novel Haemophilia Treatment—A Humanized Mouse Model to Answer Our Questions?
- 6 March 2025
- journal article
- editorial
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 125 (05) , 447-448
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?Haemophilia, 2024
- Recapitulating the immune system of hemophilia A patients with inhibitors using immunodeficient miceThrombosis Research, 2024
- Hemophilia treatment innovation: 50 years of progress and more to comeJournal of Thrombosis and Haemostasis, 2023
- Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia ANew England Journal of Medicine, 2023
- An update on the ‘danger theory’ in inhibitor development in hemophilia AExpert Review of Hematology, 2019
- Splenic marginal zone antigen‐presenting cells are critical for the primary allo‐immune response to therapeutic factor VIII in hemophilia AJournal of Thrombosis and Haemostasis, 2009